证券代码：301196 证券简称：唯科科技 公告编号：2025-027 厦门唯科模塑科技股份有限公司 1、召开时间：2025 年 5 月 15 日（星期四）15:40-17:00 2、召开方式：网络远程 3、参与方式：投资者可登录"全景路演"网站（http://rs.p5w.net），或 关注微信公众号：全景财经，或下载全景路演 APP 参与 4、公司出席人员：公司董事长兼总经理庄辉阳先生，副总经理兼董事会秘 书罗建文先生，财务总监周镇森先生，独立董事戴建宏先生，保荐机构代表人傅 志锋先生。 5、投资者问题征集及方式 为充分尊重投资者、提升交流的针对性，现就本次活动提前向投资者公开征 集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 5 月 15 日（星期四） 13:00 前将有关问题通过电子邮件的形式发送至公司投资者关系互动邮箱： vkir@vokegroup.com。届时公司高管将在线就公司 2024 年度业绩、公司治理、 关于参加厦门辖区上市公司 2024 年年报业绩说明会暨投资者网上集 体接待日活动并征集相关问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载 ...

Market Overview - On April 29, the Shanghai Composite Index fell by 0.05%, with the total margin financing balance at 1.802272 trillion yuan, a decrease of 153.6 million yuan from the previous trading day [1] - The margin financing balance in the Shanghai market was 918.038 billion yuan, down by 28.5 million yuan; in the Shenzhen market, it was 879.028 billion yuan, down by 124.2 million yuan; and in the Beijing Stock Exchange, it was 5.206 billion yuan, down by 977.97 thousand yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 12 sectors saw an increase in financing balance, with the public utilities sector leading with an increase of 315 million yuan, followed by the automotive and telecommunications sectors with increases of 260 million yuan and 106 million yuan, respectively [1] Stock Performance - A total of 1,490 stocks experienced an increase in financing balance, accounting for 40.40% of the market, with 220 stocks seeing an increase of over 5% [1] - The stock with the largest increase in financing balance was Weike Technology, with a latest financing balance of 160 million yuan, reflecting a 73.04% increase from the previous trading day, and its stock price rose by 16.78% [1] - Other notable stocks with significant increases in financing balance included Chunguang Intelligent and Sudar Co., with increases of 41.16% and 38.74%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the largest increase in financing balance, the average increase was 4.27%, with the highest gainers being Daye Co., United Chemical, and Weike Technology, with increases of 19.98%, 18.19%, and 16.78%, respectively [2] - Conversely, the stocks with the largest declines in financing balance included Shibibai, with a decrease of 60.84%, followed by Runben Co. and Huayang Racing, with declines of 41.55% and 36.34%, respectively [5][6]

Market Overview - On April 29, the Shanghai Composite Index experienced fluctuations, with a total trading volume of 1.04 trillion yuan in A-shares; over 3,500 stocks closed higher, including 76 stocks that hit the daily limit [1] - Industries such as beauty care, plastic products, chemical products, and automotive parts saw gains exceeding 2% [1] Historical Highs - A total of 19 stocks reached historical closing highs, excluding newly listed stocks from the past year; notable industries include food and beverage, automotive, and beauty care, each contributing three stocks to the list [2] - The average increase for stocks that reached historical highs was 7.43%, with stocks like Xinchao New Materials (301076) and Zhongqi New Materials (001212) hitting the daily limit [2] Top Gainers - The top gainers among stocks that reached historical highs included: - Xinchao New Materials (301076) with a closing price of 41.17 yuan and a daily increase of 19.99% - Leidi Ke (300652) with a closing price of 73.97 yuan and an increase of 18.54% - United Chemical (301209) with a closing price of 98.00 yuan and an increase of 18.19% [3] Institutional Trading - On April 29, six stocks saw institutional net purchases exceeding 10 million yuan, with Daye Co., Ltd. (300879) leading at 44.54 million yuan [4] - Conversely, seven stocks experienced net sales over 10 million yuan, with Shaoyang Hydraulic (301079) facing the highest net sell-off at 52.17 million yuan [4] Northbound Capital - Among the stocks with significant northbound capital activity, Liou Co., Ltd. (002131) and Bochuang Technology (300548) received net purchases exceeding 40 million yuan [6][7] - Stocks that saw net sales included Dongfang Tong (300379) and Zhongxin Tourism (002707) [6]

Group 1 - The company reported a revenue increase of 35.64% to 1.819 billion in 2024, with a net profit increase of 31.05% to 220 million [1] - In Q1 2025, the company achieved a revenue of 539 million, representing a year-on-year growth of 64.37% and a quarter-on-quarter growth of 12.34%, with a net profit of 77 million, showing a year-on-year increase of 105.12% and a quarter-on-quarter increase of 80.83% [1] - The company's expense ratios for sales, management, R&D, and finance were 2.47%, 8.05%, 4.37%, and -0.73% respectively, with year-on-year changes of -0.4, -3.49, -0.56, and -0.05 percentage points [1] Group 2 - Demand for new energy and health appliances is rising, leading to better-than-expected performance growth, with overseas production capacity being continuously released to strengthen competitive advantages [2] - Revenue from injection molding products increased by 38.13% to 909 million in 2024, with a gross margin increase of 0.73 percentage points to 31.57%; health products revenue rose by 42.83% to 538 million, with a gross margin decrease of 5.32 percentage points to 20.96% [2] - The company is actively expanding in the new energy sector and acquired Yuke Plastic in May 2024, benefiting from the trends in the new energy vehicle industry [2] Group 3 - The company is a key supplier for overseas giants like Kollmorgen, providing components for robots, and is advancing in the development of electronic skin [3] - The company supplies motor components and gears to major motor companies and collaborates with firms like DANFOSS to develop advanced materials for applications in components [3] - The company is working with renowned medical brand AMBU to develop plastic human skin, and its subsidiary Yuke Plastic is developing IME in-mold electronic technology, which is expected to accelerate electronic skin development [3] Group 4 - The company is projected to achieve revenues of 2.221 billion, 2.684 billion, and 3.232 billion from 2025 to 2027, with corresponding net profits of 316 million, 371 million, and 399 million, leading to P/E ratios of 23.7, 20.2, and 18.7 respectively [3]

Financial Performance - The company's operating revenue for Q1 2025 reached ¥539,491,778.48, representing a 64.37% increase compared to ¥328,208,395.63 in the same period last year[5] - Net profit attributable to shareholders was ¥77,392,822.37, a 105.12% increase from ¥37,729,915.99 year-on-year[5] - Basic earnings per share rose to ¥0.6228, up 106.02% from ¥0.3023 in the previous year[5] - The company reported a 165.02% increase in net profit after deducting non-recurring gains and losses, amounting to ¥73,549,072.93 compared to ¥27,752,147.18 in Q1 2024[5] - Net profit for the current period was ¥80,702,471.75, compared to ¥39,086,505.12 in the previous period, reflecting a growth of approximately 106.5%[26] - Earnings per share (EPS) for the current period was ¥0.6228, up from ¥0.3023 in the previous period, marking an increase of about 106.5%[27] - The company reported a comprehensive income total of ¥83,535,699.77 for the current period, compared to ¥36,778,817.23 in the previous period, representing an increase of approximately 126.6%[27] Cash Flow - The net cash flow from operating activities was ¥47,846,621.54, showing a significant increase of 199.36% compared to ¥15,983,161.36 in Q1 2024[11] - Operating cash inflow for the current period reached ¥460,800,481.46, a 29.3% increase from ¥356,088,038.07 in the previous period[28] - Cash inflow from investment activities totaled ¥633,697,936.60, down 27.3% from ¥872,010,733.79 in the prior period[29] - Net cash flow from investment activities improved to ¥110,721,497.65, up 57.9% from ¥70,106,017.37[29] - Cash outflow from financing activities decreased to ¥12,249,951.97 from ¥41,723,471.21, a reduction of 70.7%[30] - The net cash flow from financing activities was -¥11,136,730.21, an improvement from -¥41,616,926.21[30] - The ending balance of cash and cash equivalents increased to ¥586,783,860.27, compared to ¥348,233,500.99 at the end of the previous period, reflecting a 68.4% rise[30] - Tax refunds received amounted to ¥12,466,228.80, up 59.4% from ¥7,839,812.22[29] - Cash paid to employees rose to ¥126,515,795.99, a 31.4% increase from ¥96,284,731.66[29] - Cash inflow from the recovery of investments was ¥626,659,500.00, down 26.7% from ¥855,659,008.03[29] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥3,997,553,427.55, a 2.01% increase from ¥3,918,827,588.40 at the end of the previous year[5] - Total liabilities decreased slightly to ¥727,674,198.75 from ¥734,530,669.66, a reduction of about 0.9%[22] - The total equity attributable to shareholders of the parent company rose to ¥3,201,924,896.17 from ¥3,119,631,283.07, an increase of approximately 2.6%[23] - Deferred income tax assets increased to ¥31,612,600.47 from ¥26,802,149.69, reflecting a growth of approximately 17.0%[22] Research and Development - Research and development expenses increased by 45.83% to ¥23,558,256.59, reflecting the company's commitment to innovation[10] - Research and development expenses for the current period were ¥23,558,256.59, compared to ¥16,154,325.26 in the previous period, indicating an increase of about 45.7%[26] Shareholder Information - The company had a total of 16,036 common shareholders at the end of the reporting period[12] - The total number of restricted shares decreased to 57,535,350.00 from 87,482,712.00, following the release of 29,950,880.00 shares during the period[18] - The company has no significant changes in the top 10 shareholders participating in margin trading activities[14] - The company plans to maintain a stable dividend policy, with no changes in the distribution of shares among major shareholders[14] - The company has no new updates regarding preferred shareholders or changes in restricted shares[15][16] - The company’s employee stock ownership platform is managed by Xiamen City Keput Investment Partnership, with a significant holding of RMB 16,879,000.00[14] Other Information - The company experienced a 594.46% increase in current non-current assets due within one year, totaling ¥104,780,824.51, primarily due to an increase in large time deposits[9] - The company has not disclosed any new product developments or technological advancements during this reporting period[19] - There are no significant mergers or acquisitions reported in the current financial period[19] - Total operating costs amounted to ¥455,758,754.51, up from ¥295,619,407.00, indicating an increase of about 54.1%[25] - Accounts receivable increased to RMB 487,104,803.62, up from RMB 450,507,723.07, reflecting a growth of approximately 8%[20] - Inventory levels rose to RMB 409,950,439.36, compared to RMB 398,979,769.02 at the start of the period, indicating a 2.4% increase[20]

证券代码：301196 证券简称：唯科科技 公告编号：2025-025 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）第二届监事会第十五 次会议于 2025 年 4 月 28 日在厦门火炬高新区（翔安）产业区春光路 1152 号- 1156 号（双号）公司会议室以现场表决方式召开，会议通知已于 2025 年 4 月 24 日以现场送达的形式向全体监事发出，本次会议由监事会主席傅元梧先生召集并 主持，应到监事 3 名，实际出席监事 3 名。本次会议的召集和召开符合《公司法》 等相关法律、行政法规、规范性文件及《公司章程》《监事会议事规则》等有关 规定。 一、监事会会议审议情况 经与会监事审议，一致通过以下决议： 1、审议通过《关于<2025 年第一季度报告>的议案》 经审议，监事会认为：公司编制的《2025 年第一季度报告》符合相关法律法 规的规定，报告内容真实、准确、完整地反映公司 2025 年第一季度的财务状况 和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏，符合《深圳证券 交易所创业板股票上市规则》 ...

厦门唯科模塑科技股份有限公司（以下简称"公司"）第二届董事会第十六 次会议于 2025 年 4 月 28 日在厦门火炬高新区（翔安）产业区春光路 1152 号- 1156 号（双号）公司会议室以现场表决和电子通讯相结合的方式召开，会议通知 已于 2025 年 4 月 24 日以现场送达和电子邮件的形式向全体董事发出，本次会议 由董事长庄辉阳召集和主持，应到董事 7 名，实际出席董事 7 名，公司监事、高 级管理人员列席了本次会议。本次会议的召集和召开符合《公司法》等相关法律、 行政法规、规范性文件及《公司章程》《董事会议事规则》等有关规定。 一、董事会会议审议情况 经与会董事审议，一致通过以下决议： 1、审议通过《关于<2025 年第一季度报告>的议案》 经审议，董事会认为：公司编制的《2025 年第一季度报告》符合相关法律法 规的规定，报告内容真实、准确、完整地反映了公司 2025 年第一季度的财务状 况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。同意对外报出。 证券代码：301196 证券简称：唯科科技 公告编号：2025-024 厦门唯科模塑科技股份有限公司 第二届董事会第十六次会议决议公告 ...

Group 1: Company Performance Highlights - Xingchen Technology achieved revenue of 2.354 billion yuan, a year-on-year increase of 16.49%, and a net profit of 256 million yuan, up 25.18% [3] - Lida's total revenue reached 6.807 billion yuan, growing by 1.88%, with a net profit of 418 million yuan, an increase of 33.25% [6][4] - Wangsu Technology reported revenue of 4.932 billion yuan, a 4.81% increase, and a net profit of 675 million yuan, up 10.02% [6] - Yanjing Co. achieved revenue of 1.485 billion yuan, a 17.96% increase, with a net profit of 27.28 million yuan, up 30.72% [6] - Weike Technology reported revenue of 1.819 billion yuan, a 35.64% increase, and a net profit of 220 million yuan, up 31.05% [7] - Hongfa Co. achieved revenue of 14.102 billion yuan, a 9.07% increase, with a net profit of 1.631 billion yuan, up 17.09% [11] - Hongxin Electronics reported revenue of 5.875 billion yuan, a significant increase of 68.91%, and a net profit of 56.82 million yuan, up 113.05% [12] Group 2: Business Segments and Growth Drivers - Xingchen Technology's smart IoT business grew significantly, with revenue of 475 million yuan, up 38.61%, and its automotive chip business also performed well, achieving revenue of 245 million yuan, up 31.01% [3] - Lida's lighting products contributed the majority of revenue, with lighting revenue at 4.363 billion yuan, a 5.84% increase [4] - Wangsu Technology focused on CDN and edge computing, increasing R&D investment to 447 million yuan, which is 9.07% of revenue [6] - Yanjing Co. plans to enhance customer loyalty through R&D innovation and global supply chain utilization [6] - Weike Technology is expanding into precision injection molding and health products, forming a "mold-injection integration" production model [7] - Hongfa Co. maintained a leading position in relay products, with a market share increase in various segments [11] - Hongxin Electronics experienced rapid growth in its computing power segment, significantly boosting overall profitability [12]

Core Viewpoint - The company reported strong financial performance in 2024, with significant revenue growth and improved cash flow, indicating a solid operational foundation for future development [2][5]. Financial Performance - In 2024, the company achieved total revenue of 1.819 billion yuan, representing a year-on-year increase of 35.64% - The net profit attributable to shareholders was 220 million yuan, up 31.05% year-on-year - The non-recurring net profit reached 162 million yuan, reflecting a 39.58% increase year-on-year - Operating cash flow significantly increased to 320 million yuan, a remarkable growth of 103.99% year-on-year, marking a historical high [2]. Product Performance and Global Expansion - The injection molding products generated revenue of 909 million yuan, up 38.13% year-on-year, with a gross margin of 31.57% - Health products achieved revenue of 538 million yuan, a 42.83% increase year-on-year, although the gross margin decreased by 5.32% to 20.96% - Precision molds contributed 296 million yuan in revenue, a modest increase of 1.93%, with a gross margin of 39.49% - The company is expanding its overseas production capacity in Germany, Malaysia, Mexico, and Vietnam, positioning itself as one of the few domestic enterprises with a global production base [3]. R&D and Industry Applications - The company is focused on developing electronic skin technology, collaborating with AMBU to create plastic human skin for laboratory and educational use - The subsidiary, Yuke, has advanced IML technology and is developing IME technology, which can be applied to electronic and smart skin - Current products in the robotics sector include educational companion robots and automatic feeding robots, with samples of lightweight in-mold electronic products already developed [4]. Earnings Forecast - Revenue projections for 2025, 2026, and 2027 are 2.185 billion yuan, 2.691 billion yuan, and 3.192 billion yuan, respectively - Earnings per share (EPS) are forecasted to be 2.12 yuan, 2.54 yuan, and 3.01 yuan for the same years - The current stock price corresponds to price-to-earnings (PE) ratios of 27.6, 23.0, and 19.5, respectively, with a "buy" investment rating recommended [5].

Investment Rating - The report maintains a "Buy" investment rating for the company [2][10]. Core Insights - The company achieved robust growth in performance, with total revenue reaching 1.819 billion yuan in 2024, a year-on-year increase of 35.64%, and a net profit of 220 million yuan, up 31.05% year-on-year [6]. - The operating cash flow significantly increased, reaching 320 million yuan in 2024, representing a growth of 103.99% year-on-year, indicating strong operational health [6]. - The company is actively expanding its overseas production capacity, establishing a global production base with facilities in Germany, Malaysia, Mexico, and Vietnam [7]. - The company is deeply engaged in the development of electronic skin technology, collaborating with renowned medical brands and exploring applications in the robotics industry [8][9]. - Revenue forecasts for 2025-2027 are projected at 2.185 billion, 2.691 billion, and 3.192 billion yuan, respectively, with corresponding EPS of 2.12, 2.54, and 3.01 yuan [10][12]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of 1.819 billion yuan, a 35.64% increase year-on-year, and a net profit of 220 million yuan, reflecting a 31.05% growth [6]. - The operating cash flow reached a record high of 320 million yuan, marking a 103.99% increase from the previous year [6]. Product and Market Expansion - The company's injection molding products generated revenue of 909 million yuan, up 38.13% year-on-year, while healthcare products saw a revenue increase of 42.83% to 538 million yuan [7]. - The company is expanding its overseas production capabilities, positioning itself as one of the few domestic enterprises with a global production base [7]. Research and Development - The company is focusing on electronic skin technology, collaborating with AMBU for the development of plastic human skin for laboratory and educational use [8]. - The company is also developing products for the robotics sector, including educational companion robots and automated feeding robots [9]. Earnings Forecast - The company forecasts revenues of 2.185 billion yuan in 2025, 2.691 billion yuan in 2026, and 3.192 billion yuan in 2027, with EPS estimates of 2.12, 2.54, and 3.01 yuan respectively [10][12].